Drugs / Autologous Dendritic Cell-Tumor Cell Immunotherapy
Autologous Dendritic Cell-Tumor Cell Immunotherapy
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01875653 | Oct 2014 → Jan 2016 | melanoma | Lisata Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Dendritic Cell-Tumor Cell Immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01875653 ↗ |
| Modality | Cell therapy | “the patient's own dendritic cells (a type of immune cell)” NCT01875653 ↗ |
| Route | Subcutaneous | “Doses of DC-TC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.” NCT01875653 ↗ |